Literature DB >> 11737396

NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: fact or fiction?

U A Walker1, K Brinkman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11737396     DOI： 10.1046/j.1464-2662.2001.00073.x

Source DB:  PubMed          Journal:  HIV Med        ISSN： 1464-2662            Impact factor:   3.180


× No keyword cloud information.
  10 in total

1.  HIV-associated lipodystrophy syndrome: A review of clinical aspects.

Authors:  Jean-Guy Baril; Patrice Junod; Roger Leblanc; Harold Dion; Rachel Therrien; Franãois Laplante; Julian Falutz; Pierre Côté; Marie-Nicole Hébert; Richard Lalonde; Normand Lapointe; Dominic Lévesque; Lyse Pinault; Danielle Rouleau; Cécile Tremblay; Benoãt Trottier; Sylvie Trottier; Chris Tsoukas; Karl Weiss
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

2.  Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).

Authors:  N Sunil Kumar; J Shashibhushan; K Venugopal; Huggi Vishwanatha; Mahesh Menon
Journal:  J Clin Diagn Res       Date:  2015-07-01

3.  Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Authors:  P Tebas; J Zhang; R Hafner; K Tashima; A Shevitz; K Yarasheski; B Berzins; S Owens; J Forand; S Evans; R Murphy
Journal:  J Antimicrob Chemother       Date:  2009-03-19       Impact factor: 5.790

4.  Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients.

Authors:  B Lindegaard; P Keller; H Bruunsgaard; J Gerstoft; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

5.  Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals.

Authors:  Walter Rangel Lopes de Campos; Dayaneethie Coopusamy; Lynn Morris; Bongani M Mayosi; Makobetsa Khati
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

6.  Mean corpuscular volume (MCV) values reflect therapeutic effectiveness in zidovudine-receiving HIV patients.

Authors:  Ah Hyun Kim; Woori Jang; Yonggoo Kim; Yeon-Joon Park; Kyungja Han; Eun-Jee Oh
Journal:  J Clin Lab Anal       Date:  2013-09       Impact factor: 2.352

7.  Performance of Clinical Criteria for Screening of Possible Antiretroviral Related Mitochondrial Toxicity in HIV-Infected Children in Accra.

Authors:  Allison Langs-Barlow; Lorna Renner; Karol Katz; Veronika Northrup; Elijah Paintsil
Journal:  AIDS Res Treat       Date:  2013-03-07

8.  New and emerging agents in the management of lipodystrophy in HIV-infected patients.

Authors:  Eric Bonnet
Journal:  HIV AIDS (Auckl)       Date:  2010-09-17

9.  Benefits of leptin therapy in HIV patients.

Authors:  Uma Sinha; Keshab Sinharay; Nilanjan Sengupta; Prasanta Mukhopadhyay
Journal:  Indian J Endocrinol Metab       Date:  2012-12

Review 10.  Metabolic complications and treatment of perinatally HIV-infected children and adolescents.

Authors:  Linda Barlow-Mosha; Allison Ross Eckard; Grace A McComsey; Philippa M Musoke
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.